Search published articles


Showing 2 results for Vaccination.
Human papilloma virus (HPV) vaccine, prevention of cervical cancer: a review article
Sahar Seddiq, Fatemeh Khalili , Asghar Abdoli, Fatemeh Azarkish, Kamal Abdolmohammadi ,
Volume 80, Issue 3 (6-2022)
Abstract
According to the official statistics of the World Health Organization (WHO), cervical cancer is one of the most common cancers among women after breast, colorectal, and lung cancers. The US Centers for Disease Control and Prevention (CDC) says all women have the chance to get the disease, and women over the age of 30 are more likely to get it. However, this cancer is a types of cancer that can be prevented through vaccination. This study aimed to investigate the role of vaccines in the prevention of cervical cancer. In this review study, articles published between 2016-2022 from PubMed, SID, Cochrane Library, Science Direct, and Google Scholar databases were examined. Keywords Papilloma vaccine and cervical cancer in Persian sources and HPV vaccine and Cervical Cancer in English sources were used. The subject search was also performed using MeSH medical subject headings and through the Pubmed database. Vaccination against human papillomavirus is the most cost-effective public health measure against cervical cancer. In many developed and developing countries, serious programs are underway for HPV vaccination and screening for cervical cancer. In most countries, HPV vaccination has been added to their mandatory immunization programs, effectively reducing the incidence of cervical infections and cancers. In countries where vaccination is not complete, health education and screening programs such as PAP smears every 2 years for all women and every year for those with high cancer risk or abnormal smears, have been consolidated. HPV vaccination is highly effective and has been added to immunization programs in many countries. Nowadays, three types of vaccines have been presented, of which the 9-valent Gardasil vaccine is more effective than the other two types, but in terms of cost-effectiveness, the 4-valent Gardasil vaccine is more suggested. Due to the high prevalence of cervical cancer in Iran, it is suggested that the HPV vaccine be used, screening tests be optimized and performed on a regular basis, and ways to prevent cervical cancer be taught.

Outcomes of AstraZeneca vaccine for relapse and Covid-19 infection in people with multiple sclerosis
Nazanin Razazian, Mohammad-Ali Sahraian, Sharareh Eskandarieh, Nooshin Jafari, Mansour Rezaei, Negin Fakhri,
Volume 80, Issue 6 (9-2022)
Abstract
Background: People with chronic diseases of the immune system, such as multiple sclerosis (MS), are at risk for Covid-19 disease. However, more research is needed with long-term follow-up. The aim of the study was to follow up people with MS (PwMS) for up to three months after AstraZeneca vaccination for the recurrence of MS and Covid-19 infection.
Methods: This study was a case study (descriptive-analytical) of follow-up type. The study population was PwMS over 18 years of age in Kermanshah province who received both doses of the AstraZeneca vaccine. This study was conducted from August to November 2021. Sampling was done with existing methods based on the National MS Registry of Iran (NMSRI). Demographic information of patients was extracted from NMSRI. A researcher-made form was used to collect information by telephone three months after vaccination about clinical characteristics, Covid-19 infection, and recurrence of MS. Data were analyzed using SPSS-25 software.
Results: Study participants were 40 MS patients with a mean (SD) age of 39.27 (8.8) years, including 32 (80.0%) women. A mean of 9.39 (4.6) years had passed since The patients were diagnosed with MS, and 29 (76.4%) had RR type MS. Four patients (10%) relapsed between the second dose and three months later, of whom two (50%) had sensory symptoms, one (25%) had optic nerve involvement, and one (25%) had motor symptoms and pyramidal pathway involvement. The symptoms of Covid-19 were mild in three patients (10%), while severe symptoms developed in one patient (10%) who received rituximab. Among the patients, no cases of thrombosis were observed. Infusion therapy, a leg fracture, and kidney stones were the only hospitalized cases.
Conclusion: Covid-19 and MS relapse prevalence did not differ significantly in the three months before and after vaccination. There is a need for further studies with a longer follow-up period.

Page 1 from 1     

© 2024 , Tehran University of Medical Sciences, CC BY-NC 4.0

Designed & Developed by : Yektaweb